Breaking News Instant updates and real-time market news.

AVEO

Aveo Pharmaceuticals

$0.98

-0.02 (-2.00%)

, DISCA

Discovery

$30.00

-0.05 (-0.17%)

08:45
04/17/19
04/17
08:45
04/17/19
08:45

Largest borrow rate increases among liquid names

Latest data shows the largest indicative borrow rate increases among liquid option names include: AVEO Oncology (AVEO) 27.99% +0.43, Discovery (DISCA) 0.46% +0.11, Sorrento Therapeutics (SRNE) 22.66% +0.08, Zynerba (ZYNE) 40.26% +0.07, Weibo (WB) 0.35% +0.02, and Direxion Daily China Bull 3X Shares (YINN) 0.77% +0.01.

AVEO

Aveo Pharmaceuticals

$0.98

-0.02 (-2.00%)

DISCA

Discovery

$30.00

-0.05 (-0.17%)

SRNE

Sorrento Therapeutics

$4.01

-0.06 (-1.47%)

ZYNE

Zynerba

$8.30

-0.03 (-0.36%)

WB

Weibo

$70.40

1.89 (2.76%)

  • 02

    May

  • 08

    May

AVEO Aveo Pharmaceuticals
$0.98

-0.02 (-2.00%)

02/19/19
PIPR
02/19/19
NO CHANGE
Target $3
PIPR
Overweight
Aveo Pharmaceuticals should be bought on any weakness, says Piper Jaffray
Aveo Pharmaceuticals' full Phase III Tivo-3 data for tivozanib in an oral presentation on Saturday "showed clear advantage" for progression-free survival, overall response rate and safety, but the "immature" overall survival data show a hazard ratio of 1.12, Piper Jaffray analyst Edward Tenthoff tells investors in a research note. The analyst believes that with more patients still on tivozanib, the hazard ratio could slip below 1.0 and meet the FDA filing requirement. He recommends buying shares of Aveo on weakness and keeps an Overweight rating on the name with a $3 price target.
03/15/19
03/15/19
NO CHANGE

Baird reiterates Outperform rating on Aveo after Q4 earnings
Baird analyst Madhu Kumar reiterated an Outperform rating and $2 price target on Aveo Pharmaceuticals after the company reported its Q4 earnings report. The analyst said in a research note partially titled "Clinical Basis for TIVO-3 OS Optimism" that he continues to have relative optimism to the Street for Fotivda, and added that a Q4 of 2019 update on TIVO-3 OS was a key potential positive catalyst for the stock.
03/28/19
NATL
03/28/19
INITIATION
NATL
Sell
Aveo Pharma initiated with a Sell, $0 price target at National Securities
National Securities initiated Aveo Pharmaceuticals with a Sell and $0 price target saying recent share appreciation is "totally unwarranted." The firm's analyst expects interim and final Phase 3 overall survival data updates to fail to support a Tivozanib NDA filing.
04/04/19
PIPR
04/04/19
NO CHANGE
Target $3
PIPR
Overweight
Piper maintains Overweight rating, $3 target on Aveo after stock sale
Piper Jaffray analyst Edward Tenthoff maintains his Overweight rating and $3 price target on Aveo Pharmaceuticals after the company "opportunistically" raised $25M by issuing 21.7M shares at $1.15 per share and 21.7M in warrants with a $1.25 strike price. The analyst, who estimates that Aveo now holds pro forma cash of about $57M, said the primary driver for the stock remains the OS analysis for TIVO-3 that is scheduled to be reported in Q4. If the hazard ratio does not drop to less than 1.0 for tivozanib, Tenthoff does not believe the FDA will accept a new NDA filing, he noted.
DISCA Discovery
$30.00

-0.05 (-0.17%)

12/06/18
12/06/18
UPGRADE
Target $27

Hold
Discovery upgraded to Hold with unchanged $27 price target at Pivotal Research
As previously reported, Pivotal Research analyst Brian Wieser upgraded Discovery to Hold from Sell with the stock now trading close to his $27 price target and the company having revised its Q4 guidance. His talks with national TV buyers has him convinced that there may have been unrealistic expectations with respect to how much revenue the combined Scripps and Discovery might be able to realize, said Weiser, though he noted that Discovery Communications' CEO reduced expectations for Q4 advertising growth at an investor conference earlier this week citing ratings weakness at the flagship network.
12/07/18
WOLF
12/07/18
INITIATION
Target $37
WOLF
Outperform
Discovery initiated with an Outperform at Wolfe Research
Wolfe Research initiated Discovery with an Outperform and $37 price target.
01/15/19
PIVT
01/15/19
UPGRADE
Target $36
PIVT
Buy
Viacom upgraded to Buy from Hold at Pivotal Research
Pivotal Research analyst Brian Wieser upgraded Viacom (VIAB) to Buy and raised his price target for the shares to $36 from $33. The analyst cites valuation for the upgrade with greater than 15% upside to his new price target. Ahead of the Q4 earnings season, Wieser also maintains a Sell rating on Disney (DIS) and Hold ratings on CBS (CBS) and Discovery (DISCA).
04/03/19
JPMS
04/03/19
NO CHANGE
JPMS
Overweight
Discovery shares 'particularly attractive at current levels,' says JPMorgan
JPMorgan analyst Alexia Quadrani reiterates an Overweight rating on Discovery following announcements this week with the BBC, which include the creation of a global factual streaming service in a content partnership and the break-up of UKTV. The analyst finds the stock "particularly attractive at current levels with several catalysts ahead." These include a "deleveraging story," which opens the doorway for a potential share buyback, the likely inclusion on YouTube's live TV service, and improving ratings at the flagship Discovery Channel that should be positive for domestic advertising, Quadrani tells investors in a research note.
SRNE Sorrento Therapeutics
$4.01

-0.06 (-1.47%)

06/28/18
RILY
06/28/18
INITIATION
Target $14.25
RILY
Buy
Sorrento Therapeutics initiated with a Buy at B. Riley FBR
B. Riley FBR analyst Andrew D'Silva started Sorrento Therapeutics with a Buy rating and $14.25 price target.
12/12/18
HCWC
12/12/18
NO CHANGE
HCWC
Buy
Sorrento Therapeutics has multiple catalysts in 2019, says H.C. Wainwright
2019 should represent a turning point for Sorrento Therapeutics, H.C. Wainwright analyst Raghuram Selvaraju tells investors in a research note. The analyst believes the company is in position to report "multiple value-driving clinical data catalysts" over the course of 2019, both with its pain management portfolio and its cancer immunotherapy candidates. He thinks the interest in anti-CD38 CAR-T approaches has only increased following the recently concluded American Society for Hematology annual meeting. Further, Sorrento's recent financing transactions "provide a pathway to sustainability," adds Selvaraju. He reiterates a Buy rating on the shares with a $40 price target.
03/20/19
RILY
03/20/19
NO CHANGE
Target $12
RILY
Buy
B. Riley FBR boosts Sorrento target to $12, sees 'numerous' catalysts
B. Riley FBR analyst Andrew D'Silva raised his price target for Sorrento Therapeutics to $12.00 from $10.50 and maintains a Buy rating on the shares following the company's Q4 results. Following the "strong close to 2018," the analyst lowered his cash burn estimates and pushed out projected capital raises. The top- and bottom-line beats were due to higher sales and services revenue, primarily out of Scilex Pharmaceuticals, the company's majority-owned subsidiary, as ZTlido sales were recognized a quarter earlier than expected, D'Silva tells investors in a research note. The analyst, however, continues to believe the primary driving force of Sorrento's share price is "locked in its product pipeline." With "numerous high-value opportunities" that primarily extend across immuno-oncology, pain management, and animal health, D'Silva sees a positive risk/reward on the stock.
ZYNE Zynerba
$8.30

-0.03 (-0.36%)

07/05/18
HCWC
07/05/18
NO CHANGE
Target $23
HCWC
Buy
Zynerba failed program not material negative, says H.C. Wainwright
Zynerba Pharmaceuticals this morning announced it is discontinuing development of its transdermal THC pro-drug patch ZYN001 after a Phase 1 study in healthy subjects failed to deliver the targeted potential therapeutic blood levels. This development is not a material negative, H.C. Wainwright analyst Oren Livnat tells investors in a research note. The analyst says he never included ZYN001 for Tourette's or any other indication in his estimates or valuation. He notes that his valuation is entirely based on orphan designated ZYN002 transdermal cannabidiol gel for Fragile X syndrome, entering Phase 3 shortly, "with upside optionality from ongoing work in refractory and rare epilepsies." Livnat views the early-stage ZYN001 termination "as a sign of responsible drug development" and keeps a Buy rating on Zynerba with a $23 price target. The stock in afternoon trading is down 54c to $9.07.
08/06/18
HCWC
08/06/18
NO CHANGE
Target $23
HCWC
Buy
Zynerba 46% pullback since financing unwarranted, says H.C. Wainwright
Shares of Zynerba Pharmaceuticals are down 46% since the company announced a $30M financing late July, and down 30% from where it priced at $8 per share, H.C. Wainwright analyst Oren Livnat tell investors in a research note. The analyst views the stock weakness as unwarranted. The ZYN002 programs are on track for key 2019 readouts, Livnat points out. He believes Zynerba's current valuation "belies even highly risk-discounted opportunities." The analyst is "perplexed by the extreme ZYNE pullback." Livnat says he's not aware of any erosion of Zynerba's fundamentals or prospects. The analyst reiterates aBuy rating on Zynerba with a $23 price target.
09/21/18
CANT
09/21/18
INITIATION
Target $21
CANT
Overweight
Zynerba initiated with an Overweight at Cantor Fitzgerald
Cantor Fitzgerald analyst Charles Duncan last night initiated coverage of Zynerba with an Overweight rating and $21 price target. The analyst, who started coverage on seven Neuro-Innovator and Platform-Enabled Therapeutic companies, believes that "biotech has entered a golden age of innovation and productivity across many therapeutic areas."
WB Weibo
$70.40

1.89 (2.76%)

03/06/19
CHRS
03/06/19
DOWNGRADE
CHRS
Hold
Weibo downgraded to Hold from Buy at China Renaissance
China Renaissance downgraded Weibo to Hold from Buy citing fair valuation.
03/06/19
BNCH
03/06/19
NO CHANGE
Target $108
BNCH
Buy
Sina price target raised to $108 from $96 at Benchmark
Benchmark analyst Fawne Jiang raised her price target on Sina (SINA) shares to $108 from $96 based on her sum-of-the-parts analysis. Though Sina reported "slightly soft" Q4 results, Jiang believes the stock is undervalued from an asset perspective when taking into consideration the company's major ownership in Weibo (WB) and investments in multiple other valuable assets, she tells investors. Jiang keeps a Buy rating on Sina shares.
03/06/19
DBAB
03/06/19
DOWNGRADE
DBAB
Hold
Weibo downgraded to Hold from Buy at Deutsche Bank
03/06/19
DBAB
03/06/19
DOWNGRADE
DBAB
Hold
Weibo, Sina downgraded to Hold on macro, smartphone risks at Deutsche Bank
As previously reported, Deutsche Bank analyst Eileen Deng downgraded Weibo (WB) to Hold from Buy as she sees risk to the advertising industry from the macro environment and risk to MAU growth due to smartphone softness and her view on neither of those risks was changed by listening to the company's Q4 results call. She edged up her price target on Weibo shares to $71 from $70, but sees a lack of catalysts for a meaningful earnings revision, Deng said in a post-earnings note. She also downgraded Sina (SINA) to Hold from Buy with an unchanged price target of $70, stating that in addition to the risks to Weibo's financials, she sees greater impact on the Sina portal from the macro weakness and from competition.

TODAY'S FREE FLY STORIES

MINI

Mobile Mini

$34.65

0.67 (1.97%)

16:09
04/22/19
04/22
16:09
04/22/19
16:09
Earnings
Mobile Mini reports Q1 adjusted EPS 41c, consensus 38c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 23

    Apr

  • 07

    May

KIDS

OrthoPediatrics

$36.94

0.51 (1.40%)

16:09
04/22/19
04/22
16:09
04/22/19
16:09
Hot Stocks
OrthoPediatrics announces licensing partnership with CoorsTek Medical »

OrthoPediatrics Corp.…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 25

    Apr

CDNS

Cadence Design

$64.20

0.84 (1.33%)

16:09
04/22/19
04/22
16:09
04/22/19
16:09
Earnings
Cadence Design sees Q2 EPS 52c-54c, consensus 50c »

Sees Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 02

    May

ADC

Agree Realty

$64.54

-0.77 (-1.18%)

16:08
04/22/19
04/22
16:08
04/22/19
16:08
Hot Stocks
Agree Realty raises FY19 acquisition guidance view to $450M-$500M »

The company sated,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

  • 04

    Jun

ZSAN

Zosano Pharma

$3.65

0.24 (7.04%)

16:08
04/22/19
04/22
16:08
04/22/19
16:08
Initiation
Zosano Pharma initiated  »

Zosano Pharma initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RMBS

Rambus

$11.84

-0.06 (-0.50%)

16:08
04/22/19
04/22
16:08
04/22/19
16:08
Hot Stocks
Breaking Hot Stocks news story on Rambus »

Rambus sees Q2 adjusted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 25

    Apr

  • 15

    May

  • 16

    May

CDNS

Cadence Design

$64.20

0.84 (1.33%)

16:08
04/22/19
04/22
16:08
04/22/19
16:08
Earnings
Cadence Design reports Q1 adjusted EPS 54c, consensus 49c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 02

    May

RMBS

Rambus

$11.84

-0.065 (-0.55%)

16:07
04/22/19
04/22
16:07
04/22/19
16:07
Earnings
Rambus reports Q1 adjusted EPS (8c), may not compare to consensus 23c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 25

    Apr

  • 15

    May

  • 16

    May

ADC

Agree Realty

$64.35

-0.96 (-1.47%)

16:07
04/22/19
04/22
16:07
04/22/19
16:07
Earnings
Agree Realty reports Q1 Core FFO 74c, consensus 74c »

Reports Q1 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 25

    Apr

  • 04

    Jun

HMTV

Hemisphere Media

$14.78

0.09 (0.61%)

, DISH

Dish

$33.70

-1.2 (-3.44%)

16:07
04/22/19
04/22
16:07
04/22/19
16:07
Hot Stocks
Hemisphere Media: Cinelatino reaches renewal agreement with DISH Network »

Hemisphere Media (HMTV)…

HMTV

Hemisphere Media

$14.78

0.09 (0.61%)

DISH

Dish

$33.70

-1.2 (-3.44%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 29

    Apr

  • 06

    May

  • 21

    May

GES

Guess

$16.68

-0.39 (-2.28%)

16:07
04/22/19
04/22
16:07
04/22/19
16:07
Earnings
Guess affirms Q1 outlook »

The company states:…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

FB

Facebook

$181.54

3.26 (1.83%)

16:06
04/22/19
04/22
16:06
04/22/19
16:06
Hot Stocks
Facebook names State Department's Jennifer Newstead as General Counsel »

Facebook announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 24

    Apr

  • 03

    Jun

ROKU

Roku

$58.20

1.51 (2.66%)

16:04
04/22/19
04/22
16:04
04/22/19
16:04
Initiation
Roku initiated at Susquehanna »

Roku initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    May

  • 22

    May

TCFC

Community Financial

$28.96

0.06 (0.21%)

16:03
04/22/19
04/22
16:03
04/22/19
16:03
Earnings
Community Financial reports Q1 EPS 70c, consensus 64c »

Net interest income…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$76.64

-1.07 (-1.38%)

15:55
04/22/19
04/22
15:55
04/22/19
15:55
Options
NetApp put volume heavy and directionally bearish »

Bearish flow noted in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Jun

  • 09

    Jul

RTRX

Retrophin

$19.99

-0.08 (-0.40%)

15:51
04/22/19
04/22
15:51
04/22/19
15:51
Conference/Events
Retrophin management to meet with Jefferies »

Meeting to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 04

    May

  • 08

    May

  • 05

    Jun

  • 30

    Jun

BDRBF

Bombardier

$0.00

(0.00%)

15:43
04/22/19
04/22
15:43
04/22/19
15:43
Periodicals
Bombardier sees higher sales from modernizing existing rail cars, Reuters says »

Bombardier expects higher…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    May

  • 14

    May

  • 05

    Jun

DHI

D.R. Horton

$45.61

-0.815 (-1.76%)

15:40
04/22/19
04/22
15:40
04/22/19
15:40
Options
DR Horton draws call sellers after an analyst downgrade, ahead of earnings »

DR Horton draws call…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

NBL

Noble Energy

$27.78

0.66 (2.43%)

15:38
04/22/19
04/22
15:38
04/22/19
15:38
Hot Stocks
Noble Energy raises quarterly dividend 9% to 12c per share »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

  • 03

    May

RMBS

Rambus

$11.82

-0.08 (-0.67%)

15:34
04/22/19
04/22
15:34
04/22/19
15:34
Options
Rambus options imply 9.7% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 25

    Apr

  • 15

    May

  • 16

    May

TSLA

Tesla

$263.63

-9.62 (-3.52%)

, SSNLF

Samsung

$0.00

(0.00%)

15:24
04/22/19
04/22
15:24
04/22/19
15:24
Hot Stocks
Tesla confirms neural processor design custom by Tesla »

During Tesla's…

TSLA

Tesla

$263.63

-9.62 (-3.52%)

SSNLF

Samsung

$0.00

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

SBUX

Starbucks

$75.23

-0.84 (-1.10%)

15:24
04/22/19
04/22
15:24
04/22/19
15:24
Hot Stocks
Chinese Starbucks competitor Luckin Coffee files for U.S. listing »

According to the filing…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Apr

WHR

Whirlpool

$139.79

0.75 (0.54%)

15:19
04/22/19
04/22
15:19
04/22/19
15:19
Options
Whirlpool options imply 10.3% move in share price post-earnings, above median historical move »

Pre-earnings options…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 23

    Apr

TSLA

Tesla

$263.10

-10.15 (-3.71%)

, NVDA

Nvidia

$188.97

2.71 (1.46%)

15:17
04/22/19
04/22
15:17
04/22/19
15:17
Hot Stocks
Tesla able to make more specific solution than Nvidia, CEO Musk says »

Comparing to Nvidia…

TSLA

Tesla

$263.10

-10.15 (-3.71%)

NVDA

Nvidia

$188.97

2.71 (1.46%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Apr

  • 24

    Apr

  • 22

    May

  • 10

    Jun

$NSD

NASDAQ Market Internals

$0.00

(0.00%)

15:17
04/22/19
04/22
15:17
04/22/19
15:17
Technical Analysis
NASDAQ market internals summary »

Volume is average for…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.